Simplified Chinese
English
描述
Solutions for Cancer Targeted Therapy
Solutions for Cancer Targeted Therapy
Pan-cancer Comprehensive Genomic Profiling Platform
Cancer genetic test is an important method used by pharmaceutical companies to enroll clinical trial patients, study drug resistance mechanism research, and discover biomarker during the development of cancer targeted therapy. To meet the diverse research needs of researchers in these areas, Sequanta Technologies has established a comprehensive genomic profiling platform that covers different gene sizes, tumor types, and technical roadmaps. A comprehensive genomic profiling platform can meet different domestic and international regulatory requirements , ensuring that partners can select the product that best meets their clinical project needs and application scenarios to facilitate efficient research and rapid market launch of targeted drugs.
Product Features
Extensive product portfolio and customized solutions for partners
Pan-cancer Comprehensive genomic profiling platform of Sequanta Technologies covers relevant molecular alterations from multiple key oncology guidelines (NCCN, ESMO, ACMG, CSCO) and clinical trials for solid and hematologic tumors. It can detect molecular alterations such as point mutations, insertion-deletion variants, copy number variants, and fusion genes.

To improve the product line, in addition to the OncoCODE series independently developed in line with the Chinese clinical trial standards, Sequanta Technologies has introduced a variety of detection products that meet international multi-center clinical trial standards, such as the FoundationOne series and TSO500 series, covering different gene sizes, tumor types, technical roadmaps and analytes, with ability to provide customized panel design, validation and detection services according to study objectives.

Sequanta Technologies is the only clinical trial testing service provider for FoundationOne CDx in China. Foundation One and TSO500 have been approved by the FDA and Europe for concomitant diagnosis of tumor-targeted drugs. Sequanta Technologies has performed more than 10,000 Foundation One CDx tests, providing international multi-center clinical trials and companion diagnostic (CDx) development services for pharmaceutical companies.
Covering biomarker in guidelines
The analysis platform covers a variety of tumor treatment guidelines (NCCN, ESMO, ACMG, CSCO), clinical trials and biomarkers of pathways related to tumorigenesis and development, maximizing the possibility of finding positive biomarkers from patient biopsies and providing customers and partners with higher quality biomarker detection services.
描述
Service Advantages
Excellent product performance with strict validation
Pan-cancer comprehensive genomic profiling products of Sequanta Technologies have been validated by Sequanta Laboratories to meet CAP/CLIA standards, including accuracy studies, precision studies, and limit of detection studies, and have passed CAP, NCCL, SCCL, and other domestic and international inter-laboratory quality assessments with perfect scores, thus fully meeting the performance requirements of regulatory agencies for test in clinical trials .
描述
Successful Cases
描述
Contact us
240 Hedan Road, Waigaoqiao Pilot Free Trade Zone, Shanghai, China
Shanghai International Biomedical Science & Innovation Center info@sequanta.com
021-20500599
Copyright: Shanghai Sequanta Technologies Co., Ltd. Record No.: Shanghai
ICP Record No. 2021028059-1